Wobble Genomics is pioneering a novel diagnostic platform that leverages full-length RNA sequencing from blood samples to identify low-abundance RNA biomarkers, which can significantly enhance the accuracy of cancer diagnostics. Their proprietary technologies, Level-Up and TAMA, work in tandem to unlock previously hidden RNA sequences. Level-Up is a biochemical technology that amplifies the representation of low-abundance RNA, allowing for the detection of a vast array of unique full-length RNA sequences without prior knowledge of their composition. TAMA, on the other hand, is a bioinformatics tool that optimizes the identification of low-level RNA signals, facilitating a deeper understanding of the data derived from long-read RNA sequencing.

The application of these technologies has shown promising results, particularly in early-stage breast cancer detection, where Wobble Genomics achieved an impressive 80% sensitivity at 95% specificity. In a recent clinical study, the company identified over 600,000 RNA transcripts per patient, many of which were previously unrecognized, highlighting the potential of their platform to provide critical insights into cancer biology. This innovative approach not only aims to improve early detection and monitoring of cancer but also seeks to inform treatment decisions and enhance drug development, ultimately contributing to better patient care in oncology.

United Kingdom

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers. The company has raised significant investment to accelerate biotechnology innovations and has a team of 10 employees.

Various

Ground Floor Orchard Brae House, 30 Queensferry Road, Suite 2, Edinburgh EH4 2HS, Scotland, United Kingdom

Wobble Genomics

Company Details